Bristol-myers Squibb Compnay

Other

Bristol Meyers Squibb Company

Bristol-myers Squibb

Piyasena Hewawasam

John A Bender

John F Kadow

Nicholas A Meanwell

Kap-Sun Yeung

Min Ding

John E Starrett, Jr

Katharine A Grant-Young

Robert G Gentles

Ying Han

Xiaofan Zheng

Kyle E Parcella

Yong Tu

Thomas W Hudyma

Scott W Martin

Paul Michael Scola

Omar D Lopez

Valentin K Gribkoff

Makonen Belema

Sing-Yuen Sit

Li-Qiang Sun

Jeffrey Lee Romine

Xi Chen

Gan Wang

Louis Stanley Chupak

Alan Xiangdong Wang

David R Langley

Mark George Saulnier

Jeffrey Allen Campbell

Van N Nguyen

David Bertil Frennesson

Feng He

John K Thottathil

Andrew Charles Good

Yan Chen

Denis R St Laurent

Ny Sin

Kenneth M Boy

Eric Mull

Timothy P Connolly

Tao Wang

Zhongxing Zhang

Brett R Beno

Andrew Nickel

Ningning Xu

Zhong Yang

Carl P Bergstrom

Gene G Kinney

Juliang Zhu

Samayamunthula Venkata Satya Arun Kumar Gupta

Steven Dworetzky

Richard Pracitto

Dalton King

Xiangdong Alan Wang

Yadagiri R Pendri

Pierre Dextraze

Zhaoxing Meng

Qi Chen

Eduardo J Martinez

Li-Quang Sun

Lawrence B Snyder

Yong-Jin Wu

Alicia Regueiro-Ren

Jie Chen

Rico Lavoie

Min Gao

Hasibur Rahaman

Michael J Smith

Alexandre L'Heureux

Huan He

Jean-Paul Daris

Fiona McPhee

Julie A Lemm

Kai Xie

Ying-Kai Wang

Nicholas J Lodge

Robert A Fridell

Daniel J Tenney

Pothukanuri Srinivasu

Stephen G Swartz

Donald R O'Boyle, Ii

Jin-Hua Sun

Roshan Yadavrao Nimje

John A Easter

Bao-Ning Su

Indasi J Gopi Kumar

Suresh Kumar Ponugupati

Indasi Gopi Kumar

Ponugupati Suresh Kumar

Chunfu Wang

Davidb Frennesson

Suresh Kumar Punugupati

Donald R O'BOYLE Ii

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Compounds for the treatment of hepatitis C

The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Growing community of inventors

Middletown, CT, United States of America

Piyasena Hewawasam